3 New Strong Buy Ratings from Top-Rated Analysts: 09/18/2026
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Progyny (PGNY): Fertility benefits adoption is accelerating and this stock is benefiting
- PTC Therapeutics (PTCT): Experts believe it has 80%+ upside potential
- Eton Pharmaceuticals (ETON): 250%+ return on equity and several Strong Buy recommendations
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
1. Progyny (NASDAQ: PGNY)
This benefits company specializes in fertility and family-building solutions for employers across the United States. The company is capturing strong momentum as market adoption of fertility benefits expands and utilization trends rebound.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $27.35 — get current quote
Max 1-year forecast: $40.00
Why we're watching:
- PGNY has strong, bullish coverage among the analysts we track, with 7 Strong Buy, 1 Buy, and 2 Hold recommendations. See all recommendations here
- For example, BTIG researcher David Larsen (a top 19% rated analyst) recently maintained his Strong Buy rating with a price target that suggests the stock could see greater than 40% upside in the coming year.
- Industry ranking context: PGNY is currently the #2 highest-rated stock in the Health Information Service industry, which has an Industry Rating of A.
- Zen Ratings highlights: PGNY earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all 4,600+ stocks tracked based on a rigorous 115-factor fundamental review.
- Component Grades: PGNY excels for Financials with an A grade, reflecting strong operational efficiency and an 8% profit margin, while maintaining solid Bs for Growth and Safety, a combination that positions it well for continued appreciation in the expanding fertility benefits market. See all 7 Component Grades here
2. Eton Pharmaceuticals (NASDAQ: ETON)
With an impressive 30.8% profit margin and accelerating revenue growth forecasted at 40% annually, this rare-disease-focused pharma company is executing on its strategy to expand its product pipeline and market presence.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $56.75 — get current quote
Max 1-year forecast: $70.00
Why we're watching:
- ETON has limited, but overall bullish, coverage among the analysts we track, with 2 Strong Buy and 2 Buy recommendations. See all recommendations here
- For example, HC Wainwright & Co. researcher Swayampakula Ramakanth (a top 2% rated analyst) recently maintained his Buy rating with a price target suggesting the stock could see roughly 25% upside in the coming year.
- Industry ranking context: ETON is currently the #2 highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
- Zen Ratings highlights: ETON earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: ETON stands out with elite As for Financials, Growth, and Momentum, demonstrating exceptional operational performance with a 30.8% profit margin and extraordinary return on equity of 264%, along with a strong B for Sentiment, positioning it as a compelling rare disease play. See all 7 Component Grades here
3. PTC Therapeutics (NASDAQ: PTCT)
This pharma company focused on rare genetic diseases is driving excitement with its expanding pipeline and recent data releases demonstrating broad patient benefits from its novel treatments.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $67.61 — get current quote
Max 1-year forecast: $130.00
Why we're watching:
- PTCT has solid, bullish coverage among the analysts we track, with 7 Strong Buy and 1 Hold recommendations. See all recommendations here
- For example, Barclays researcher Eliana Merle (a top 14% rated analyst) recently maintained her Strong Buy rating with a price target that suggests the stock could see greater than 80% upside in the coming year.
- Separately, Jefferies researcher Faisal Khurshid (a top 6% rated analyst) recently upgraded their recommendation to Strong Buy, citing new patient build models suggesting revenues should continue to beat expectations.
- Industry ranking context: PTCT is currently the #14 highest-rated stock in the Biotech industry, which has an Industry Rating of F.
- Zen Ratings highlights: PTCT earns an overall A rating, which equals a Strong Buy recommendation. This tier represents stocks that have passed a comprehensive 115-factor fundamental analysis, identifying them among the top investment opportunities in the market.
- Component Grades: PTCT earns a strong A for Growth, reflecting robust revenue expansion and promising pipeline developments, along with a solid B for Sentiment, indicating positive analyst and market reception despite the challenges facing the broader biotech sector. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.